Multicenter Pivotal Clinical Trial of Urine Malaria Test for Rapid Diagnosis of *Plasmodium falciparum* Malaria

Wellington A. Oyibo,*a Nnenna Ezeigwe,b Godwin Ntadom,b Oladipo O. Oladosu,a Kaitlin Rainwater-Loveth,c Wendy O’Meara,d Evaezi Okpokoro,e William Briegerc

ANDI Centre of Excellence for Malaria Diagnosis, International Malaria Microscopy Training and Rapid Diagnostic Test Quality Assurance Programme, and WHO/TDR/FIND Malaria Specimen Bank Site, College of Medicine, University of Lagos, Lagos, Nigeria*a; National Malaria Elimination Program, Federal Ministry of Health, Abuja, Nigeriab; Johns Hopkins University School of Public Health, Baltimore, Maryland, USAc; Duke University School of Medicine, Durham, North Carolina, USAd; Institute of Human Virology Nigeria, Abuja, Nigeriae

**ABSTRACT** The need to expand malaria diagnosis capabilities alongside policy requirements for mandatory testing before treatment motivates exploration of noninvasive rapid diagnostic tests (RDTs). We report the outcome of the first cross-sectional, single-blind clinical performance evaluation of a urine malaria test (UMT) for diagnosis of *Plasmodium falciparum* malaria in febrile patients. Matched urine and finger-prick blood samples from participants ≥2 years of age with fever (axillary temperature of ≥37.5°C) or with a history of fever in the preceding 48 h were tested with UMT and microscopy (as the gold standard). BinaxNOW (Pf and Pan versions) blood RDTs were done to assess relative performance. Urinalysis and rheumatoid factor (RF) tests were conducted to evaluate possible interference. Diagnostic performance characteristics were computed at 95% confidence intervals (CIs). Of 1,800 participants screened, 1,691 were enrolled; of these 566 (34%) were febrile, and 1,125 (66%) were afebrile. Among enrolled participants, 341 (20%) tested positive by microscopy, 419 (25%) were positive by UMT, 676 (40%) were positive by BinaxNOW Pf, and 368 (22%) were positive by Binax NOW Pan. UMT sensitivity among febrile patients (for whom the test was indicated) was 85%, and specificity was 84%. Among febrile children ≤5 years of age, UMT sensitivity was 93%, and specificity was 83%. The area under the receiver-operator characteristic curve (AUC) of UMT (0.84) was not significantly different from that of BinaxNOW Pf (0.86) or of BinaxNOW Pan (0.87), indicating that the tests do not differ in overall performance. Gender, seasons, and RF did not impact UMT performance. Leukocytes, hematuria, and urobilinogen concentrations in urine were associated with lower UMT specificities. UMT performance was comparable to that of the BinaxNOW Pf/Pan tests, making UMT a promising tool to expand malaria testing in public and private health care settings where there are challenges to blood-based malaria diagnosis testing.

**KEYWORDS** health care provider, malaria, noninvasive malaria test, *Plasmodium falciparum*, point-of-care diagnosis, primary healthcare setting, rapid diagnostic test (RDT), urine malaria test (UMT)

The current WHO recommendation for parasitological confirmation of suspected malaria cases prior to treatment is a paradigm shift from entrenched presumptive diagnostic practices. Annually, there are 214 million estimated cases of malaria globally (1). Despite increasing parasitological diagnosis capabilities in countries of endemicity, universal access to testing in cases of fever suspected of being induced by malaria remains a major challenge, particularly in community and private health care settings. This is due in part to limited access to quality-assured microscopy, laboratory infra-
structure requirements, blood safety concerns, and regulatory/policy requirements that forbid nonlaboratory professionals from undertaking invasive diagnostic procedures.

Among 18 nationally representative surveys conducted in Africa from 2013 to 2015, the median proportions of febrile children receiving malaria testing was 53% in public health facilities, 36% in the formal private sector, and 6% in the informal private sector, with only 12.6% of febrile children being tested in Nigeria (2, 3). Therefore, there is substantial opportunity for malaria diagnoses, particularly in the private health care sector, where most fevers are managed (3). Consequently, if the goal of universal access to diagnosis is to be achieved and national and international diagnosis targets are to be met, novel technologies will play a significant role. Progress in diagnostic coverage requires wider access to safe, effective, low-cost, and easy-to-use tests at primary-level points of care, including community health workers, private clinics, pharmacies, medicine shops, and front-line government health facilities. Several new tests are under development, such as technologies that target parasite antigen (e.g., fluorescent RDTs) and hemozoin, a point-of-care test for spectroscopy, and serology, which is currently commercially available as ELISA tests in blood bank screening in developed countries (4–6). Among these tests, the urine malaria test (UMT) developed by Fyodor Biotechnologies, Inc. (Baltimore, MD, USA), is the only nonblood malaria test that has undergone a full-scale premarket evaluation trial.

Previous attempts to use urine and saliva for malaria diagnosis in blood-based RDTs produced poor performance (7–13). The UMT is a simple, immuno-chromatographic dipstick that utilizes recombinant monoclonal antibody to detect highly repetitive cognate polyhistidine-rich protein 2 (HRP-2) and fragments thereof shed in the urine of febrile patients (D. J. Sullivan and P. Scholl, U.S. patent application 20090117602). A pilot field study that tested the UMT in 203 febrile patients showed a sensitivity of 83.75%, specificity of 83.48%, positive predictive value (PPV) of 77.91%, and negative predictive value (NPV) of 88.07% (14), indicating the viability of an accurate urine-based malaria test. The study enrolled predominantly children (73.8%), and the outcome also indicated the need for a larger study population to broaden the range of patients, including those without objective fever at presentation.

Here, we report the outcome of a pivotal multicenter clinical performance evaluation of the UMT in Lagos State, Nigeria.

RESULTS

Demographics and clinical characteristics of patients. Of 1,800 participants screened, 1,691 (94%) were enrolled per eligibility criteria, with a mean age (± standard deviation [SD]) of 18.6 years (SD of 15.9; range, 2 to 80), of whom 970 were female (57%) and 721 were male (43%). Among these 1,691 enrollees, 566 (34%) participants were febrile (≥37.5°C), and 1,125 (66%) were afebrile but reported a history of fever in the previous 48 h (Table 1). Headache, body pain, and chills were the most commonly reported symptoms in both groups. Normal urine ketone levels, pH, and specific gravity were observed in 80%, 85%, and 75% of participants, respectively.

Malaria prevalence. Malaria prevalence varied among the overall, febrile, and afebrile participant populations. Overall, 341 (20%) of 1,691 enrollees were microscopy-positive for malaria (Table 2). The UMT detected malaria in 419 (25%) of participants, while BinaxNOW tests that detect the HRP-2 antigen of Plasmodium falciparum (BinaxNOW Pf) and aldolase, a pan-malaria antigen found in all Plasmodium species (BinaxNOW Pan), detected malaria in 676 (40%) and 368 (22%) of participants, respectively. The highest prevalence was among febrile participants. Among 566 febrile participants, 204 (36%) were positive by microscopy, 231 (41%) were positive by UMT, 224 (40%) were positive by BinaxNOW Pan, and 317 (56%) were positive by BinaxNOW Pf. Similarly, febrile participants had higher parasite densities (PDs) than afebrile participants (Table 2) (2). Three participants with monospecies Plasmodium malariae infection by microscopy were negative by UMT and BinaxNOW Pf, while two of them were positive by BinaxNOW Pan. These monospecies samples were excluded in the analyses.
TABLE 1 Demographic characteristics and clinical history of the study population

| Parameter             | Overall (n = 1,691) | Febrile (n = 566) | Afebrile (n = 1,125) |
|-----------------------|---------------------|-------------------|----------------------|
| Gender                |                     |                   |                      |
| Female                | 970 (57)            | 276 (49)          | 694 (62)             |
| Male                  | 721 (43)            | 290 (51)          | 431 (38)             |
| Age (yr)              |                     |                   |                      |
| 2–5                   | 416 (25)            | 202 (36)          | 214 (19)             |
| 6–11                  | 390 (23)            | 175 (31)          | 215 (19)             |
| 12–17                 | 195 (12)            | 81 (14)           | 114 (10)             |
| 18–20                 | 61 (4)              | 20 (4)            | 41 (4)               |
| 21–39                 | 427 (25)            | 71 (13)           | 356 (32)             |
| 40–54                 | 153 (9)             | 13 (2)            | 140 (12)             |
| 55+                   | 49 (3)              | 4 (1)             | 45 (4)               |
| Symptoms              |                     |                   |                      |
| Chills                | 1,135 (67)          | 442 (78)          | 693 (62)             |
| Body pain             | 1,159 (69)          | 387 (68)          | 772 (69)             |
| Headache              | 1,364 (81)          | 473 (84)          | 891 (69)             |
| Vomiting              | 257 (15)            | 129 (23)          | 128 (11)             |
| Stomach ache          | 185 (11)            | 128 (23)          | 57 (5)               |
| Weakness              | 68 (4)              | 56 (10)           | 12 (1)               |
| Anorexia              | 186 (11)            | 86 (15)           | 100 (9)              |
| Cough                 | 189 (11)            | 117 (21)          | 72 (6)               |
| Catarrh               | 170 (10)            | 107 (19)          | 63 (6)               |
| Bitter taste          | 31 (2)              | 25 (4)            | 6 (1)                |
| Dizziness             | 46 (3)              | 35 (6)            | 11 (1)               |
| Other                 | 83 (5)              | 25 (4)            | 58 (5)               |
| Study site            |                     |                   |                      |
| Agura                 | 365 (22)            | 75 (13)           | 290 (26)             |
| Bayekun               | 218 (13)            | 88 (16)           | 130 (12)             |
| Ijede                 | 522 (31)            | 206 (36)          | 316 (28)             |
| Imota                 | 439 (26)            | 164 (29)          | 275 (24)             |
| Oreta                 | 48 (3)              | 6 (1)             | 42 (4)               |
| Shomolu               | 99 (6)              | 27 (5)            | 72 (6)               |

*aThe mean age ± SD for each group was as follows: overall, 18.6 ± 15.9 years (range, 2.0 to 80 years); febrile, 11.6 ± 11.0 years (range, 2.0 to 70 years); afebrile, 22.1 ± 16.7 years (range, 2.0 to 80 years).*

**Performance of the UMT.** (i) **Febrile participants.** UMT sensitivity among the 566 febrile participants was 85% (95% confidence interval [CI], 79, 89), and specificity was 84% (95% CI, 80, 88) (Table 3). Among febrile children of ≤5 years of age, UMT sensitivity was 93% (95% CI, 80, 98), and specificity was 83% (95% CI, 75, 89). Compared to UMT, BinaxNOW Pf sensitivity was high (99% [95% CI, 97, 100]), while specificity was low (69% [95% CI, 64, 74]) (both P < 0.001). The sensitivity and specificity of BinaxNOW Pan did not differ significantly from those of UMT, while PPVs and NPVs did not differ significantly between UMT and either of the BinaxNOW tests. The negative likelihood ratio (NLR) for UMT differed from that of BinaxNOW Pf and was closer to that of BinaxNow Pan, while the positive likelihood ratio (PLR) for UMT was also closer to that of BinaxNow Pan than to that of BinaxNOW Pf (Table 3).

(ii) **Afebrile patients.** Of 1,125 afebrile participants, UMT sensitivity was 72%, and while it did not significantly differ from that of BinaxNOW Pan (72%) (P = 1.00), sensitivity was significantly lower than that of BinaxNOW Pf (97%) (P = 0.001) (Table 3). The specificities of UMT and BinaxNOW Pan among afebrile participants were 91% (95% CI, 89, 93) and 95% (94, 97), respectively, and significantly higher than the specificity of BinaxNOW Pf (77% [95% CI, 74, 80]) (P < 0.001). The likelihood ratios also varied among the tests.

(iii) **Overall study population (febrile and afebrile).** Overall UMT sensitivity and specificity for all participants (febrile and afebrile combined) were 79% (95% CI, 75, 84) and 89% (96% CI, 87, 91), respectively. UMT sensitivity did not differ from that of BinaxNOW Pan (80%) but was significantly lower than that of BinaxNow Pf (98% [95%
CI: 96, 98]) (P < 0.001) (Table 3). Specificity was higher than that of the BinaxNOW Pf test (75% [95% CI, 72, 77]) and lower than that of BinaxNOW Pan (93% [95% CI, 92, 94]) (both, P < 0.001). The PPV and NPV were 75% and 94%, respectively, for all tests and did not differ significantly from each other. The BinaxNOW Pf also differed from UMT and BinaxNOW Pan with respect to NLR and PLR values in the general study population (Table 3).

**Overall diagnostic value of UMT and BinaxNOW tests.** The values of the area under the receiver-operator characteristic (ROC) curves (AUCs) for UMT (P = 0.212), BinaxNOW Pf (P = 0.054), and BinaxNOW Pan (P = 0.358) did not differ between febrile and afebrile participants (all, P > 0.05) (Table 4). A pooled AUC calculated for each diagnostic test (Fig. 1) showed that the UMT (0.84 [95% CI, 0.82, 0.87]) was not significantly different from the BinaxNOW Pf (0.86 [95% CI, 0.85, 0.89]) or BinaxNOW Pan (0.87 [95% CI, 0.84, 0.89]) test, suggesting that the tests do not differ in overall performance.

**Other performance characteristics.** Graded PDs by microscopy compared with UMT performance showed that increased PD was associated with increased probability of fever (P < 0.001). UMT, BinaxNOW Pf, and BinaxNOW Pan sensitivities increased with higher PDs among all patients, as well as with stratified subpopulations of febrile and afebrile patients (Table 5). While BinaxNOW Pf sensitivity was highest across PDs and

| Parameter                     | Overall (n = 1,691) | Febrile (n = 566) | Afebrile (n = 1,125) |
|-------------------------------|---------------------|-------------------|----------------------|
| **Positive malaria diagnostic tests** |                     |                   |                      |
| Microscopy                    | 341 (20.2)          | 204 (36)          | 137 (12.2)           |
| UMT                           | 419 (25)            | 231 (41)          | 188 (17)             |
| BinaxNOW Pf                   | 676 (40)            | 315 (56)          | 361 (32)             |
| BinaxNOW Pan                  | 368 (22)            | 224 (40)          | 144 (13)             |
| **Parasite prevalence**       |                     |                   |                      |
| Detectable asexual stage parasites | 338 (20)          | 203 (36)          | 155 (14)             |
| Density (no. of parasites)*   |                     |                   |                      |
| 1–199                         | 2 (1)               | 1 (0.5)           | 1 (1)                |
| 200–499                       | 16 (5)              | 5 (2)             | 11 (7)               |
| 500–999                       | 20 (6)              | 8 (4)             | 12 (8)               |
| 1,000–4,999                   | 70 (21)             | 34 (17)           | 36 (23)              |
| 5,000–9,999                   | 44 (13)             | 26 (13)           | 18 (12)              |
| 10,000–49,999                 | 109 (32)            | 75 (37)           | 34 (22)              |
| 50,000+                       | 77 (23)             | 54 (27)           | 23 (15)              |

| Parameter                     | Overall (n = 1,691) | Febrile (n = 566) | Afebrile (n = 1,125) |
|-------------------------------|---------------------|-------------------|----------------------|
| **Urinalysis**                |                     |                   |                      |
| Leukocytes >15/μl             | 189 (11)            | 67 (12)           | 182 (16)             |
| Presence of nitrates (mg/dl)  | 22 (1)              | 7 (1)             | 15 (1)               |
| Urobilinogen of ≥1 mg/dl      | 159 (9)             | 67 (12)           | 92 (8)               |
| Protein of ≥100 mg/dl         | 73 (4)              | 42 (7)            | 31 (3)               |
| Ketone of ≥5 mg/dl            | 344 (20)            | 176 (31)          | 168 (15)             |
| Bilirubin of ≥1 mg/dl         | 159 (9)             | 71 (13)           | 88 (8)               |
| Glucose (mg/dl)               | 21 (1)              | 5 (1)             | 16 (1)               |
| Blood (erythrocytes/μl)       | 175 (10)            | 77 (14)           | 98 (9)               |
| pH <7                         | 1,443 (85)          | 493 (87)          | 950 (84)             |
| 7                             | 114 (7)             | 45 (8)            | 69 (6)               |
| >7                            | 130 (8)             | 27 (5)            | 103 (9)              |
| Specific gravity              |                     |                   |                      |
| <1.010                        | 549 (32)            | 158 (28)          | 391 (35)             |
| 1.011–1.020                   | 725 (43)            | 264 (47)          | 461 (41)             |
| >1.021                        | 414 (24)            | 144 (25)          | 270 (24)             |

+aAsexual parasite stage only.
+bPercentages in subcategories of parasite density were calculated as number of patients in the density subcategory/total number of patients with detectable asexual parasites.
stratified subpopulations, the UMT and BinaxNOW Pan specificities were higher than the specificity of BinaxNOW Pf.

The sensitivities of all tests decreased with increasing age and increased with higher PDs. In contrast, specificities of all tests were significantly higher in adults than in younger participants in the overall study population (all, \( P < 0.001 \)). The PPVs of UMT did not differ between age categories, but while NPVs of children and adolescents were significantly lower than those of adults (\( P < 0.001 \)), all values were >90% in each category. Upon stratification by fever, the majority of the performance characteristics of the three tests did not differ significantly between the oldest and youngest participants.

Gender and season (dry and rainy) did not affect UMT performance. Urinalysis revealed that a higher number of leukocytes (>15) was associated with a significantly higher specificity (\( P = 0.001 \)), while hematuria was associated with significantly lower specificity (\( P = 0.001 \)). UMT specificity was lower among participants with urobilinogen concentrations of ≥1 mg/dl than in those with levels of <1 mg/dl (\( P < 0.001 \)). Specific gravity, which indicates urine concentration, was not associated with UMT performance. All of the 15 rheumatoid factor-positive (RF) participants tested negative for malaria and were negative by UMT.

### TABLE 3 Performance of urine malaria test and blood-based RDTs in overall study participants and febrile and afebrile subjects at clinical presentation

| Group and parametera | Test performanceb | P valuec |
|----------------------|------------------|----------|
|                      | UMT              | BinaxNOW Pf | BinaxNOW Pan | UMT vs BinaxNOW Pf | UMT vs BinaxNOW Pan |
| All participants (n = 1,691) |                  |            |               |                   |                      |
| Sensitivity (% [95% CI]) | 79 (75, 84) | 98 (96, 99) | 80 (76, 84) | <0.001 | 0.824 |
| Specificity (% [95% CI]) | 89 (87, 91) | 75 (72, 77) | 93 (92, 94) | <0.001 | <0.001 |
| PPV (% [95% CI]) | 65 (60, 69) | 50 (46, 53) | 74 (70, 79) | 1.00 | 0.988 |
| NPV (% [95% CI]) | 94 (93, 96) | 99 (99, 100) | 95 (94, 96) | 0.932 | 1.00 |
| NLR | 0.23 (0.23, 0.24) | 0.02 (0.02, 0.03) | 0.21 (0.21, 0.22) | 1.00 | 0.988 |
| PLR | 7.2 (7.2, 7.3) | 3.9 (3.9, 3.9) | 11.5 (11.3, 11.8) | 1.00 | 0.988 |

Febrile participants (n = 566)

|                      | UMT              | BinaxNOW Pf | BinaxNOW Pan | UMT vs BinaxNOW Pf | UMT vs BinaxNOW Pan |
|----------------------|------------------|            |               |                   |                      |
| Sensitivity (% [95% CI]) | 85 (79, 89) | 99 (97, 100) | 86 (80, 90) | <0.001 | 0.883 |
| Specificity (% [95% CI]) | 84 (80, 88) | 69 (64, 74) | 86 (83, 90) | <0.001 | 0.176 |
| PPV (% [95% CI]) | 75 (69, 80) | 64 (59, 69) | 78 (72, 83) | 1.00 | 0.981 |
| NPV (% [95% CI]) | 91 (87, 94) | 99 (97, 100) | 92 (88, 94) | 0.693 | 0.808 |
| NLR | 0.18 (0.17, 0.19) | 0.01 (0.01, 0.04) | 0.16 (0.16, 0.17) | 1.00 | 0.981 |
| PLR | 5.3 (5.1, 5.5) | 3.2 (3.1, 3.2) | 6.3 (6.1, 6.6) | 1.00 | 0.981 |

Afebrile participants (n = 1,125)

|                      | UMT              | BinaxNOW Pf | BinaxNOW Pan | UMT vs BinaxNOW Pf | UMT vs BinaxNOW Pan |
|----------------------|------------------|            |               |                   |                      |
| Sensitivity (% [95% CI]) | 72 (63, 79) | 97 (93, 99) | 72 (64, 80) | <0.001 | 1.00 |
| Specificity (% [95% CI]) | 91 (89, 93) | 77 (74, 80) | 95 (94, 97) | <0.001 | <0.001 |
| PPV (% [95% CI]) | 52 (45, 59) | 37 (32, 42) | 69 (61, 76) | 1.00 | 0.981 |
| NPV (% [95% CI]) | 96 (94, 97) | 99 (99, 100) | 96 (95, 97) | 0.938 | 1.00 |
| NLR | 0.31 (0.30, 0.32) | 0.04 (0.02, 0.06) | 0.29 (0.28, 0.30) | 1.00 | 0.981 |
| PLR | 7.9 (7.7, 8.1) | 4.2 (4.2, 4.2) | 15.9 (15.1, 16.6) | 1.00 | 0.981 |

aPPV, positive predictive value; NPV, negative predictive value; NLR, negative likelihood ratio; PLR, positive likelihood ratio.
bBinaxNOW Pf contains HRP-2, a *P. falciparum*-specific antigen, and BinaxNOW Pan contains aldolase, an antigen found in all species of *Plasmodium*. *P. falciparum* is the most dominant species in the trial area.
c\( P \) values comparing the sensitivities and specificities of the Fyodor UMT and the BinaxNOW tests were estimated using McNemar’s test. \( P \) values comparing the positive and negative predictive values were calculated using the weighted generalized score statistic.

### TABLE 4 Area under the ROC curve for all tests stratified by presence of fever

| Test               | AUC (95% CI) | Febrile | Afebrile | P valuea |
|--------------------|-------------|---------|----------|----------|
| UMT                | 0.84 (0.81, 0.88) | 0.81 (0.78, 0.84) | 0.212   |
| BinaxNOW Pf        | 0.84 (0.81, 0.87) | 0.87 (0.85, 0.89) | 0.054   |
| BinaxNOW Pan       | 0.86 (0.83, 0.89) | 0.84 (0.81, 0.87) | 0.358   |

a\( P \) values comparing the area under the receiver-operator characteristic (ROC) curves were computed using DeLong’s test for two ROC curves.
The original microscopy results showed that 365 individuals were infected with *Plasmodium* parasites: 362 (99%) were infected with *P. falciparum*, and 3 (1%) were infected with *P. malariae*. A further analysis of these samples by PCR showed that seven study samples originally found to harbor *P. falciparum* by microscopy were negative by PCR. Additionally, 58 microscopy-negative samples were positive by PCR; of these 56 were infected with *P. falciparum*, and 2 were infected with *P. malariae*. The PCR results of one participant sample indicated infection with *Plasmodium ovale*, but the source of the infection was originally identified by microscopy as *P. falciparum*.

The six participants infected with non-*P. falciparum* parasites as determined by PCR were removed from the data set. There were no statistically significant differences between original and PCR-corrected microscopy results of discordant samples by UMT and BinaxNOW Pf/Pan, likely reflecting high-quality microscopy methods and well-trained microscopists (Table 6).

The original microscopy results indicated that 361 study participants were infected with *P. falciparum*, while PCR-corrected microscopy results indicated that 410 participants had *P. falciparum* malaria, and the urine malaria test indicated that 451 partici-
pants were infected with *P. falciparum*. UMT sensitivities, specificities, and predictive values changed by less than 3% regardless of whether all study participants, febrile participants, or afebrile participants were assessed, by between 0 and 7% for BinaxNOW Pf, and by between 0 and 11% for BinaxNOW Pan. Overall, the largest changes occurred

### TABLE 5
Sensitivity and specificity of UMT, BinaxNOW Pf, and BinaxNOW Pan tests by parasite density level for febrile, afebrile, and all study participants

| Group and test | Test performance by parasite density<sup>a</sup> | P value by density group<sup>b</sup> |
|----------------|-----------------------------------------------|-------------------------------------|
|                | Specificity (% [CI]) at 0                     | Sensitivity (% [CI]) 1–999 1,000–4,999 5,000+ | 1–999 1,000–4,999 |
| Total study population |                                     |                                     |  |
| UMT             | 89 (87, 91)                                  | 58 (41, 74) 69 (56, 79) 86 (81, 90) | <0.001 0.002 |
| BinaxNOW Pf     | 75 (72, 77)                                  | 95 (82, 99) 96 (88, 99) 100 (98, 100) | 0.055 0.042 |
| BinaxNOW Pan    | 93 (92, 94)                                  | 42 (26, 59) 70 (58, 80) 90 (85, 93) | <0.001 <0.001 |
| Febrile group   |                                     |                                     |  |
| UMT             | 84 (80, 88)                                  | 71 (42, 92) 76 (59, 89) 88 (81, 92) | 0.105 0.107 |
| BinaxNOW Pf     | 69 (64, 74)                                  | 93 (66, 100) 97 (85, 100) NA         | 0.083 0.181 |
| BinaxNOW Pan    | 86 (83, 90)                                  | 57 (29, 82) 79 (62, 91) NA           | 0.004 0.143 |
| Afebrile group  |                                     |                                     |  |
| UMT             | 91 (89, 93)                                  | 50 (29, 71) 61 (43, 77) 82 (71, 90) | <0.001 0.020 |
| BinaxNOW Pf     | 77 (74, 80)                                  | 96 (79, 100) 94 (81, 99) 99 (93, 100) | 0.055 0.253 |
| BinaxNOW Pan    | 95 (94, 97)                                  | 33 (16, 55) 61 (43, 77) 90 (81, 96) | <0.001 0.001 |

<sup>a</sup>Parasite density (number of parasites/microliter of blood) was determined by microscopy. NA, not available.

<sup>b</sup>P values are based on a comparison with the results from the 5,000+ density group using Fisher’s exact test.

### TABLE 6
Urine malaria test (UMT) performance characteristics among study participants infected with *Plasmodium falciparum* relative to original and PCR-corrected microscopy results

| Parameter and group<sup>a</sup> | Original microscopy | PCR-corrected microscopy | P value<sup>b</sup> |
|-------------------------------|---------------------|--------------------------|---------------------|
| Sensitivity (% [CI])          |                     |                          |                     |
| All participants              | 78 (74, 83)         | 77 (72, 81)              | 0.665               |
| Febrile                       | 85 (79, 89)         | 81 (75, 86)              | 0.577               |
| Afebrile                      | 72 (64, 79)         | 72 (66, 79)              | 1.00                |
| Specificity (% [CI])          |                     |                          |                     |
| All participants              | 90 (89, 91)         | 92 (90, 93)              | 0.368               |
| Febrile                       | 84 (80, 88)         | 85 (81, 89)              | 0.770               |
| Afebrile                      | 92 (90, 93)         | 94 (92, 95)              | 0.091               |
| PPV (% [CI])                  |                     |                          |                     |
| All participants              | 63 (58, 67)         | 70 (65, 74)              | 1.00                |
| Febrile                       | 74 (68, 80)         | 77 (71, 82)              | 1.00                |
| Afebrile                      | 51 (44, 57)         | 63 (56, 69)              | 1.00                |
| NPV (% [CI])                  |                     |                          |                     |
| All participants              | 95 (94, 96)         | 94 (93, 95)              | 0.945               |
| Febrile                       | 90 (87, 93)         | 88 (84, 91)              | 0.891               |
| Afebrile                      | 97 (95, 97)         | 96 (95, 97)              | 0.941               |
| PLR                           |                     |                          |                     |
| All participants              | 0.240 (0.237, 0.243) | 0.253 (0.249, 0.256)     |                     |
| Febrile                       | 0.201 (0.195, 0.207) | 0.228 (0.221, 0.236)     |                     |
| Afebrile                      | 0.304 (0.298, 0.311) | 0.294 (0.287, 0.302)     |                     |
| NLR                           |                     |                          |                     |
| All participants              | 7.87 (7.72, 8.03)   | 9.25 (9.11, 9.40)        |                     |
| Febrile                       | 5.29 (5.04, 5.55)   | 5.49 (5.29, 5.70)        |                     |
| Afebrile                      | 8.70 (8.42, 8.99)   | 11.20 (10.9, 11.5)       |                     |

<sup>a</sup>PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio.

<sup>b</sup>P values were estimated by the chi-square statistic for sensitivity and specificity and by the weighted generalized score method for predictive values.
among the positive predictive values (PPVs), but this was expected as a mathematical relationship between prevalence and PPV value is known, whereby increasing prevalence always produces an increased PPV. Likelihood ratios also did not demonstrate clinically meaningful changes.

In contrast to microscopy results, those for sensitivity, specificity, and negative predictive values changed by less than 3% regardless of which participant population, total, febrile, or afebrile, was assessed. The largest changes occurred among the positive predictive values (PPVs), with differences between the original and PCR-corrected microscopy results ranging from 3% to 12%. However, this was expected as a mathematical relationship between prevalence and the PPV value is known, whereby increasing prevalence always produces an increased PPV. Likelihood ratios also did not demonstrate clinically meaningful changes.

**DISCUSSION**

The UMT is the first noninvasive malaria test clinically evaluated on a large scale at the population and community levels. Given its sensitivity and specificity, a disease prevalence of 20% in the study population, and a PLR of 7.2, the posterior probability of disease in a patient who tests positive by the UMT is 59%. Given the NLR of 0.23, the posterior probability of disease in a patient who tests negative by UMT is 4%. This indicates that the UMT could aid in the clinical management of suspected malaria cases. For example, upon receiving a negative UMT result for a suspected malaria case, the clinician now knows that this patient’s probability of having malaria parasites detectable by microscopy is unlikely, i.e., only 4%. In contrast, a positive UMT result would indicate that the probability of detecting malaria parasites in this patient by microscopy is 59%.

The performance of UMT was higher among febrile participants (who are the intended use population) than among afebrile individuals. High rates of false positives and lower specificities reported among HRP-2-based blood RDTs corroborate our findings (15–20) and are worrisome in spite of their high sensitivity. Broader clinical utility of a rapid malaria test should be based on its overall diagnostic value using the AUC of the receiver-operator characteristics. Our data support a role for the UMT as a diagnostic or screening tool at the control phase in countries with high to medium malaria transmission rates. However, test performance may be lower in low-transmission regions or preelimination countries, as reported for blood RDTs (21–25). Nevertheless, field evaluation studies in different transmission settings would provide performance data on UMT to demonstrate its utility.

It should be noted that *P. falciparum* parasitemia and antigenemia do not correlate directly due to sequestration, while there are no data on the correlation between parasitemia and antigenuria. Therefore, UMT performance metrics must be established de novo and not on the basis of antigenuria reported by RDTs.

The availability of the blood-based RDTs has greatly increased malaria testing particularly in the public sector, where about 53% of patients with malaria-like symptoms are tested. In the formal and informal private sector health care settings, only 36% and 6%, respectively, of patients are tested (26). The UMT could potentially expand malaria testing in private health care settings, particularly in hard-to-reach locations or health care facilities where blood draw is difficult or impractical for microscopy, and advance the current global effort toward universal diagnosis in cases of fever suspected of being malaria.

Viral hemorrhagic fevers (such as Ebola viral disease [EVD]) are major global health concerns where the UMT could be invaluable. The Ebola viral proteins connected with infection are present in blood and other body fluids at the time of fever and onset of symptoms (27, 28) but are rarely found in patient urine (29, 30). Thus, in outbreak situations, the UMT could potentially offer a safer and rapid diagnostic tool to rule out malaria as the cause of fever, particularly in rural communities with severely limited laboratory facilities.
Conclusion. Programmatically, the UMT could expand access to prompt parasitological confirmation of malaria in public and private health care settings, particularly in areas or settings where invasive blood testing is impractical or restricted.

MATERIALS AND METHODS

Study area. The study was conducted in six health care facilities (HFs) across Ikorodu (rural/suburban) and Somolu (urban) local government areas (LGAs) of Lagos State, southwest Nigeria. Malaria is hypo-mesoendemic in Lagos State, with peak transmission during the rainy season (April to September). Ikorodu LGA and Somolu LGA have estimated populations of 535,619 and 402,763, respectively.

Study sites. The HFs in Ikorodu LGA were the following: Imota Primary Health Center (PHC), Imota; Agura PHC, Gberigbe; Ifeji Health Center, Ijede; Bayekun PHC, Bayeku; Annex of St. Kizito Clinic/PHC, Oreta; and General Hospital, Somolu, Somolu LGA, Lagos State, Nigeria.

Study design and enrollment criteria. This cross-sectional, single-blind, multicenter clinical performance study screened 1,800 participants of both genders (≥2 years of age) who presented with fever (axillary temperature, ≥37.5°C) or history of fever in the past 48 h. Fifteen blood smear-negative rheumatoid factor positive (RF+) individuals were enrolled and tested to determine potential cross-reactivity with UMT, as RF is known to elicit proteinuria and cross-reactivity with HRP-2-based RDTs (31–33). Individuals who reported use of antimalarial medications within the last 2 weeks and those with severe disease were excluded. The study was conducted from July 2013 to February 2014 and covered the rainy and dry seasons.

Power and sample size justification. Simulations for the joint confidence region of sensitivity and specificity showed that at least 1,300 study participants with fever or history of fever were required, powered at 80% at a 0.05 limit of indifference (Fisher’s exact conditional test for two proportions and Walter’s normal approximation), assuming that 40% of subjects would have positive blood smears, based on the “Nigeria Malaria Indicator Survey 2010” (3).

Sample collection and handling. Upon enrollment, a case report form was completed for each participant. Matched finger-prick blood and urine samples were collected for malaria microscopy, RDT, UMT, and urinalysis. Blood spots were prepared from finger-prick blood samples on Whatman filter paper (GE Healthcare Life Science, United Kingdom). RF testing was done on a cohort of microscopy-negative patients.

UMT technology and procedure. The UMT technology relies on the fact that in clinical malaria, febrile patients shed elevated levels of proteins, including P. falciparum proteins, in urine (9), and the test detects HRP-2 shed in the urine of individuals infected with malaria. The UMT (Fyodor Biotechnologies, Inc., Baltimore, MD, USA) was performed per the manufacturer’s instructions. Briefly, a test strip was dipped into a labeled 2-ml test tube containing 200 μl of urine and incubated for 10 min. The strip was removed and incubated for 15 min at room temperature, after which the result was read. No clinical decision regarding patient care was made based on UMT results.

BinaxNOW (Pf/Pan) malaria RDT, urinalysis, rheumatoid arthritis test (RF test), and dry blood spot procedure. The BinaxNOW (Pf/Pan) blood-based malaria RDT (Alere, Inc., Waltham, MA, USA) is a qualitative immunochromatographic assay that detects HRP-2 antigen found in P. falciparum (BinaxNOW Pf), and aldolase, a pan-malaria antigen found in all Plasmodium species (BinaxNOW Pan). The test was performed per the manufacturer’s instructions and was used as a comparator RDT. Multianalyte urinalysis reagent strips (Rapid Labs, Essex, United Kingdom) were used to measure glucose, bilirubin, specific gravity, ketones, blood, pH, protein, urobilinogen, nitrates, serum creatinine, and leukocytes. A direct slide test was used to detect RF (Arlington Scientific, Inc., USA). All tests were performed per the manufacturer’s instruction.

Malaria microscopy. Thick and thin malaria blood films (MBFs) were prepared on the same slide in HFs and transported to the ANDI Center of Excellence for Malaria Diagnosis at the University of Lagos for microscopy. Two WHO-accredited malaria microscopists blinded to UMT and blood RDT (BinaxNOW Pf/Pan) results read the MBFs independently. Asexual parasites were counted relative to 200 to 1,000 leukocytes in thick films. Computed parasite density (PD) was reported as the number of parasites/microliter of blood using the mean PD of the two microscopists if discordance was ≤20%. Discordance in PDs of >20% between the two microscopists required reading by a third WHO level 1 microscopist, and the PD was recomputed incorporating this microscopist’s findings.

PCR. PCR corrections of microscopy on discordant test results were performed within the scope of another study in collaboration with Stanford University using primers targeting the Pfr364 repetitive element (34) for P. falciparum detection and the pan-Plasmodium 18S rRNA gene (35, 36).

Ethical consideration/study quality assurance. Written informed consent/assent was obtained from each participant and/or parent/guardian. This study was conducted in accordance with good clinical practice and guidance from the Nigerian Health Research Ethics Code. Patients with positive malaria RDT results were treated per national malaria diagnosis and treatment guidelines. The study was approved by the Ethics Committee of the College of Medicine, University of Lagos, Nigeria. The Lagos State Ministry of Health approved the use of HFs. A Data and Safety Monitoring Committee reviewed study and data management processes. Independent study audits were undertaken by the Nigerian National Agency for Food, Drug Administration and Control, and by Regulatory and Quality Solutions, LLC, Murrysville, PA. Study protocol and reporting conformed to the standards for reporting of diagnostic accuracy. The study has been registered at ClinicalTrials.gov under registration number NCT01921413.

Statistical analyses. Microscopy was the gold standard (reference test) for sensitivity and specificity calculations. Parasite density (number of parasites per microliter of blood) was computed for all positive
MBFs. Exact binomial confidence intervals were calculated for sensitivity, specificity, and positive and negative predictive values (PPVs and NPVs, respectively). McNemar’s test was used to compare sensitivities and specificities between diagnostic tests. The weighted generalized score method was used to compare predictive values (37). The chi-square test was used to compare the number of participants testing positive by each rapid test across categorical variables. Fisher’s exact test was used to compare the number of participants testing positive by each rapid test across dichotomous variables when appropriate. A Cochran-Mantel-Haenszel test was used to compare the odds of detecting malaria parasites by microscopy between 24- and 48-h fever durations among participants who tested positive by each rapid test. All analyses were conducted in R, version 3.0.1 (http://www.R-project.org/), using the packages epicalc, pROC, and ROCR.

ACKNOWLEDGMENTS

We gratefully acknowledge the Lagos State Ministry of Health for approving the study to be conducted in health facilities in the state and the Federal Ministry of Health/National Malaria Elimination Program, Abuja, Nigeria, for donation of doses of artemisinin-based combination therapies (ACTs). The contributions of the staff of Ijede, Bayekun, Agura, Imota, St. Kizito, and Somolu health facilities are appreciated for their support in patient enrollment and care during the study. We express our gratitude to Benjamin Pinsky and Jesse Wassogner at Stanford University for performing the PCR studies. The Research Grants and Experimentation Ethics Committee of the College of Medicine University of Lagos and Nigeria National Agency for Food and Drug Administration and Control (NAFDAC) are kindly acknowledged for protocol monitoring and site audit. We thank Tolu Arowolo for support with site monitoring.

Fyodor Biotechnologies is acknowledged for providing the urine malaria test (UMT) kits and funding for the study.

We declare that we have no financial or other personal interests in Fyodor. The decision to publish and the content are solely those of the authors.

REFERENCES

1. World Health Organization. 2015. World malaria report 2015. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/publications/world-malaria-report-2015/en/.
2. D’Acremont V, Lengeler C, Genton B. 2010. Reduction in the proportion of fevers associated with Plasmodium falciparum parasitaemia in Africa: a systematic review. Malaria J 9:240. https://doi.org/10.1186/1475-2875-9-240.
3. National Malaria Elimination Programme, National Population Commission, National Bureau of Statistics, ICF International. 2016. Nigeria malaria indicator survey 2015: key indicators. Abuja, Nigeria, and Rockville, MD. https://dhsprogram.com/pubs/pdf/MIS8/MIS8.pdf.
4. Malaria Diagnostics Technology Market Landscape UNITAID. 2011. World Health Organization, Geneva, Switzerland. 2nd Edition.
5. UNITAID. 2013. 2013 Malaria diagnostics technology market landscape, 2nd ed. World Health Organization, Geneva, Switzerland.
6. UNITAID. 2014. 2014 Malaria diagnostics technology market landscape, 2nd ed. World Health Organization, Geneva, Switzerland.
7. Nwakama DC, Gomez-Escobar N, Walther M, Crozier S, Dubovsky F, Malkin E, Locke E, Conway DJ. 2009. Quantitative detection of Plasmodium falciparum in saliva and blood. J Infect Dis 199:1567–1583. https://doi.org/10.1086/598856.
8. Buppan P, Putaporntrip C, Pattanawong U, Seethamchai S, Jonvuttiwes S. 2010. Comparative detection of Plasmodium vivax and Plasmodium falciparum DNA in saliva and urine samples from symptomatic malaria patients in a low endemic area. Malaria J 9:72. https://doi.org/10.1186/1475-2875-9-72.
9. Rodriguez-del Valle M, Quakyi IA, Amuesi J, Quaye JT, Nkrumah F, Taylor DW. 1991. Detection of antigen and antibodies in urine of humans with Plasmodium falciparum malaria. J Clin Microbiol 29:1236–1242.
10. Genton B, Patg S, Beck HP, Gibson N, Alpers MP, Hill J. 1998. Diagnosis of Plasmodium falciparum infection using Parasight-F test in blood and urine of Papua New Guinean children. Southeast Asia J Trop Med Public Health 29:35–40.
11. Pieroni P, Mills CD, Ohr C, Harrington MA, Kain KC. 1998. Comparison of the ParaSight-F test and the ICT Malaria Pf test with the polymerase chain reaction for the diagnosis of Plasmodium falciparum malaria in travellers. Trans R Soc Trop Med Hyg 92:166–169. https://doi.org/10.1016/S0033-9203(98)90730-1.
12. van den Ende J, Vervoort V, Van Gompel A, Lynen L. 1998. Evaluation of two tests based on the detection of histidine rich protein 2 for the diagnosis of imported Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 92:285–288. https://doi.org/10.1016/S0033-9203(98)91013-6.
13. Elendu JA, Oyibo W. 2014. Performance of HRP2-based malaria rapid diagnostic test (SD-Bioline) in whole blood and saliva in patients in Lagos state. Int J Innov Appl Stud 9:642–647.
14. Ogouwu T, Shu E, Ezeonwbu BU, Lige B, Derrick A, Umeh RE, Agbo E. 2014. The performance evaluation of a urine malaria test (UMT) kit for the diagnosis of malaria in individuals with fever in south-east Nigeria: cross-sectional analytical study. Malaria J 13:403. https://doi.org/10.1186/1475-2875-13-403.
15. Mishra B, Samantaray JC, Kumar A, Mirdha BR. 1999. Study of false positivity of two rapid antigen detection tests for diagnosis of Plasmodium falciparum. J Clin Microbiol 37:1233.
16. Verle P, Binh LN, Lieu TT, Coozemans M. 1996. ParaSight-F test to diagnose malaria in hypo-endemic and epidemic prone regions of Vietnam. Trop Med Int Health 1:794–796.
17. Humar A, Ohr C, Harrington MA, Pillai D, Kain KC. 1997. ParaSight-F test compared with the polymerase chain reaction and microscopy for the diagnosis of Plasmodium falciparum malaria in travelers. Am J Trop Med Hyg 56:44–48.
18. Murray CK, Bennet JW. 2009. Rapid diagnosis of malaria. Interdiscip Perspect Infect Dis 2009:415953.
19. Singer S, Mseye L, Knebel MU. 2004. Evaluation of a malaria rapid diagnostic test for assessing the burden of malaria during pregnancy. Am J Trop Med Hyg 70:481–485.
20. Hopkins H, Kambale W, Staedke SG, Drssey G, Rosenthal PJ. 2007. Comparison of HRP-2 and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampa, Uganda. Am J Trop Med Hyg 76:1090–1097.
21. Abeke TA, Kristan M, Jones C, Beard J, Mueller DH, Okia M, Rauquoda B, Greenwood B, Cox J. 2008. Determinants of the accuracy of rapid diagnostics tests in malaria case management: evidence from low and
moderate transmission settings in the East African highlands. Malaria J 7:202. https://doi.org/10.1186/1475-2875-7-202.

22. Chinkhumba J, Skarbinski J, Chilima B, Campbell C, Ewing V, San Joaquin M, Sande J, Ali D, Mathanga D. 2010. Comparative field performance and adherence to test results of four malaria rapid diagnostic tests among febrile patients more than five years of age in Blantyre, Malawi. Malaria J 9:209. https://doi.org/10.1186/1475-2875-9-209.

23. Luchavez J, Lintag ME, Coll-Black M, Baik F, Bell D. 2007. An assessment of various blood collection and transfer methods used for malaria rapid diagnostic tests. Malar J 6:149.

24. Malthe J, Guiraud I, Lombo P, Kaboré B, Gillet P, Van Geet C, Tinto H, Jacobs J. 2014. Accuracy of PfHRP2 versus Pf-pLDH antigen detection by malaria rapid diagnostic tests in hospitalized children in a seasonal hyperendemic malaria transmission area in Burkina Faso. Malaria J 13:20. https://doi.org/10.1186/1475-2875-13-20.

25. Tarimo ER, Ratsimbasoa A, Randriamanantena A, Raherinjafy R, Rasooari-lala N, Menard D. 1999. Which malaria rapid test for Madagascar? Field and laboratory evaluation of three tests and expert microscopy of samples from suspected malaria patients in Madagascar. Am J Trop Med Hyg 76:481–485.

26. UNITAID. 2016. 2016 Malaria diagnostics technology and market landscape, 3rd ed. World Health Organization, Geneva, Switzerland.

27. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Lee WF, Spiropoulou CF, Ksiazek TG, Lukwiya M, Kaducu F, Downing R, Nichol ST. 2004. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78:4330–4341. https://doi.org/10.1128/JVI.78.8.4330-4341.2004.

28. Ksiazek TG, Rollin PE, Williams AJ, Bressler DS, Martin ML, Swanepoel R, Burt FJ, Lemar PA, Khan AS, Rowe AK, Mukunu R, Sanchez A, Peters CJ. 1999. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S177–S187. https://doi.org/10.1086/514321.

29. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE. 2007. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196(Suppl 2):S142–S147. https://doi.org/10.1086/520545.

30. Rodriguez LL, De Roo A, Guimard Y, Trappier SG, Sanchez A, Bressler D, Williams AJ, Rowe AK, Bertolli J, Khan AS, Ksiazek TG, Peters CJ, Nichol ST. 1999. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis 179(Suppl 1):S170–S176. https://doi.org/10.1086/514291.

31. Adebajo AO, Cavston TE, Hazleman BL. 1994. Rheumatoid factors in association with rheumatoid arthritis and infectious diseases in West Africans. J Rheumatol 21:968–969.

32. Tighe H, Carson DA. 1997. Rheumatoid factors, p 241–249. In Kelly H (ed), Textbook of rheumatology, 5th ed. Saunders, Philadelphia, PA.

33. Iqbal J, Sher A, Rab A. 2000. Plasmodium falciparum histidine-rich protein 2-based immunochromatographic diagnostic assay for malaria: cross-reactivity with rheumatoid factors. J Clin Microbiol 38:1184–1186.

34. Sullivan DJ, Jr, Gluzman IY, Goldberg DE. 1996. Plasmodium hemochrom formation mediated by histidine-rich proteins. Science 271:219–222. https://doi.org/10.1126/science.271.5246.219.

35. Demas A, Oberstaller J, DeBarry J, Lucchi NW, Srinivasamoorthy G, Sumari D, Kabanywanyi AM, Villegas L, Escalante AA, Kachur SP, Barnwell JW, Peterson DS, Udhayakumar V, Kissinger JC. 2011. Applied genomics: data mining reveals species-specific malaria diagnostic targets more sensitive than 18S rRNA. J Clin Microbiol 49:2411–2418. https://doi.org/10.1128/JCM.02603-10.

36. Waggoner JJ, Abeynayake J, Balaiano I. 2014. Multiplex nucleic acid amplification test for diagnosis of dengue fever, malaria, and leptospirosis. J Clin Microbiol 52:2011–2018. https://doi.org/10.1128/JCM.00341-14.

37. Kosinski AS. 2013. A weighted generalized score statistic for comparison of predictive values of diagnostic tests. Stat Med 32:964–977. https://doi.org/10.1002/sim.5587.